EC Number |
Application |
Reference |
---|
1.1.1.62 | diagnostics |
17beta-HSD1 is highly expressed in breast and ovary tissues and represents a prognostic marker for the tumor progression and survival of patients with breast cancer and other estrogen-dependent tumors |
740542 |
1.1.1.62 | diagnostics |
a high HSD17B1 to HSD17B2 ratio, as well as high HSD17B1 on its own is associated with worse prognosis and increased risk of recurrence in patients with ERalpha-positive tumors. An increased copy number of the HSD17B1 gene is correlated with decreased breast cancer survival |
762074 |
1.1.1.62 | diagnostics |
the expression of 17beta-hydroxysteroid dehydrogenases 1 and 2 alone and in combination predicts outcome of patients with breast cancer |
762074 |
1.1.1.62 | diagnostics |
the mouse monoclonal antibody for AKR1C3, 10B10, is highly specific and sensitive for detecting AKR1C3 expression including patient samples. The proper detection of AKR1C3 expression is critical for therapeutics targeting AKR1C3, 10B10 will be a valuable tool in clinic for AKR1C3 precision therapy. 10B10 is specific to AKR1C3 protein and has a very low cross-activity against other AKR1 proteins |
762480 |
1.1.1.62 | drug development |
several 17beta-HSD isozymes are targets for drug development with importance in cancer, metabolic diseases, neurodegeneration and possibly immunity |
675983 |
1.1.1.62 | drug development |
the enzyme constitutes an interesting therapeutic target for estrogen-dependent diseases |
760541 |
1.1.1.62 | drug development |
the enzyme is considered a promising drug target against estrogen-dependent cancers |
740542 |
1.1.1.62 | medicine |
17beta-HSD1 inhibitors such as STX1040 may provide a treatment for hormone-dependent breast cancer |
687146 |
1.1.1.62 | medicine |
17beta-HSD1 is an attractive target for the treatment of mammary tumours |
685552 |
1.1.1.62 | medicine |
17beta-HSD1 is overexpressed in many breast tumors. Thus, it is an attractive target for the treatment of these diseases |
688272 |